←
Bimal Desai19,046 posts
Bimal Desai avatar

Bimal Desai

@bimald

Professor of Pharmacology, UVASOM. All views personal | I study ion channels and Ca2+ signaling in immunity & tissue homeostasis. RTs may not be endorsements.

◷ Joined July 2009▧ 185 Photos and videos
𝕐o̴g̴ avatar
⟳ Bimal Desai retweeted
𝕐o̴g̴@Yoda4ever·11h

Working from home..🐕🐑🐑😅

0:09
Headquarters avatar
⟳ Bimal Desai retweeted
Headquarters@HQNewsNow·2h

REMINDER: This is the 23-year-old in charge of counterterrorism measures at Trump's DHS.

Post attachment

Trump’s DOGE cut the Cybersecurity and Infrastructure Security Agency (CISA) by 30% in early 2025. Nearly 1,000 employees that dealt with cybersecurity threats and hackers were fired or forced out.

Post attachmentPost attachment
Fang Wu avatar
⟳ Bimal Desai retweeted
Fang Wu@WUFang40615703·Nov 17

“Wet-lab validated.” AI binder design papers keep reporting impressive hit rates. But does it bind in a second lab? One independent retest: only 29/107 published AI-designed nanobodies showed binding—and 6 of those had high aggregation. Germinal stands out for the wrong reason: just 1 of 12 published binders showed detectable binding on retest—a result that warrants an explanation. How much trust should we put in headline hit rates? Read more on my blog 👇 smiles724.github.io/blog/ai-…

Post attachment
Melinda B. Chu avatar
⟳ Bimal Desai retweeted
Melinda B. Chu@MelindaBChu1·5h

If you expect 10x return, then Isomorphic valuation is expected to be $500 billion. Only 3 Pharma companies have market cap that high: Eli Lilly, J&J and Abbvie and J&J is not just pharma, it’s consumer and diversified across medical decixes. Isomorphic has no drugs and even if they got an IND now; none would be approved in next 7 years. You can’t speed up the evaluation of cancer, if your endpoint is PFS. Not due to regulatory delays; just biology. No amount of money or AI can shorten the evaluation of PFS. They can’t sell their model as a SaaS b/c thats the whole supposedly unique R&D differentiation. Also, they could never be a $500 billion company off 1 model Idk how things work, but it seems like it’s a tax write off of some kind.

despite clinical promise. How much do the investors expect to make from platforms like isomorphics?

ClassicConservative 🇺🇲🇺🇲🇺🇲 avatar
⟳ Bimal Desai retweeted
ClassicConservative 🇺🇲🇺🇲🇺🇲@ReturnToReagan·Nov 17

Whether you are a Republican or a Democrat, we should all favor reducing the power and scope of executive orders. This country was not meant to be ruled by one president regardless of their party.

Democrat Senator Elissa Slotkin says the quiet part out loud: “We need to make sure that we are thinking very hard about how to Trump-proof the government going forward so that no leader can do this again.”

0:15
Jay Patrick Berube avatar
⟳ Bimal Desai retweeted
Jay Patrick Berube@jayvberube·15h

Ginkgo Bioworks deserves an award for being one of the most spectacularly unsuccessful biotech businesses I’ve ever encountered. 2023: $893 million lost. 2024: $547 million lost. 2025: $313 million lost. That’s $1.75 BILLION in GAAP net losses against just $649 million in revenue. It’s almost like they hired an anti-CEO whose primary objective was to lose more money than the company could generate. At this point, the consistency is genuinely impressive. I attended a Ginkgo event years ago, and I remember laughing at the almost religious enthusiasm surrounding the company. Dinosaurs, grandiose visions of engineering life, and people talking as though biological science fiction were already commercial reality. Question the business model, and suddenly everyone acts like you’ve insulted the future of humanity. And from my experience, trying to engage with this kind of corporate culture is almost comical. Endless meetings, elaborate etiquette, polished presentations, and seemingly infinite layers of bureaucracy. A thousand conversations to accomplish what should require one. It’s as though corporate aesthetics have become the product, while execution is merely an inconvenient afterthought. Ginkgo seems remarkably accomplished at engineering the appearance of innovation while struggling to engineer a profitable business. Perhaps management should temporarily abandon its ambitions to “revolutionize” biology and attempt something more challenging for them: operating a profitable hot dog stand. I’m fairly confident a group of high school students could demonstrate better financial discipline. Imagine losing nearly three times your total revenue over three years and still being celebrated as a visionary biotechnology enterprise. The scientific ambition is extraordinary. The commercial results are extraordinarily disappointing. My prediction: By 2030, Ginkgo will announce some glorious “transformational strategic acquisition,” celebrate the redistribution of its assets, and present the entire affair as another miraculous triumph of ingenuity and innovation. The press release will be magnificent. The financial history will be considerably less flattering. Perhaps the company’s greatest innovation will be joining the dinosaurs in extinction while calling it evolution. At some point, biotechnology needs to stop confusing corporate theater with scientific execution. #BiotechHype

Post attachment

This is not about Gingko, but it used to be you don’t have your own lab; you’re not a real biotech. Now Isomorphic being praised for having no labs (they also have no drugs.) Virtual biotech is not new (15-20 years), but Isomorphic is unsuccessful at it. “Staffing up for clinical trials.” CROs are great, but seems like you need people that are or think like Basic Scientists / Translational Researchers to direct the labs or do experiments 👩🏻‍🔬 before you need people to run trials, which make more sense to be outsourced to Parexel or IQVIA, MedPace; PPD etc. then an AI x Bio company running clinical trials and not doing any translational research? 🧐 We all know they are fake job postings to make it seem like they’ll have clinical trials soon. …Some think none until 2030.

Andrew Feinberg avatar
⟳ Bimal Desai retweeted
Andrew Feinberg@AndrewFeinberg·15h

Imelda Marcos (with her late husband) holds the Guinness record for most money looted from a government by a public official — estimated at around $30 billion

“We love you!” @POTUS tells former First Lady Imelda Marcos ❤️

0:15
Bimal Desai avatar
Bimal Desai@bimald·20h

The DOGE clusterfuck will reverberate for another decade.

Trump’s DOGE cut the Cybersecurity and Infrastructure Security Agency (CISA) by 30% in early 2025. Nearly 1,000 employees that dealt with cybersecurity threats and hackers were fired or forced out.

Post attachmentPost attachment
Melinda B. Chu avatar
⟳ Bimal Desai retweeted
Melinda B. Chu@MelindaBChu1·22h

This is not about Gingko, but it used to be you don’t have your own lab; you’re not a real biotech. Now Isomorphic being praised for having no labs (they also have no drugs.) Virtual biotech is not new (15-20 years), but Isomorphic is unsuccessful at it. “Staffing up for clinical trials.” CROs are great, but seems like you need people that are or think like Basic Scientists / Translational Researchers to direct the labs or do experiments 👩🏻‍🔬 before you need people to run trials, which make more sense to be outsourced to Parexel or IQVIA, MedPace; PPD etc. then an AI x Bio company running clinical trials and not doing any translational research? 🧐 We all know they are fake job postings to make it seem like they’ll have clinical trials soon. …Some think none until 2030.

$5B for a drug company that has said they want to do all their lab work via CROs / in the cloud! Very excited for where things are headed with AI + autonomous labs -- appreciate the leadership from @demishassabis on thinking about the drug dev process from first principles 👏👏

Melinda B. Chu avatar
⟳ Bimal Desai retweeted
Melinda B. Chu@MelindaBChu1·Nov 17

I can not quote tweet b/c he blocked me, but you should notice he put the words “accelerate” and “rapid” and “radically cut timelines” in his post. It’s been 5+ years. Your timelines are behind schedule especially for your funding. There is nothing accelerated or rapid about Isomorphic’s progress in 5+ years. They do not have any human studies or even any specific preclinical data. Milestone: Hassabis, Max and staff are able to sell a lot on the Secondaries though, so I guess that’s good for them. To everyone, who said I’m dumb and they will def have human studies in 2026, there is “more to announce in 2027” and will be “hundreds of drugs” Ok, why not just have 1 to start?

Post attachment
Bimal Desai avatar
Bimal Desai@bimald·22h

The concerning aspect of the ongoing measles outbreak is that the US has an alarmingly large number of people on immunosuppressants. The odds of contracting measles are high in this cohort even if vaccinated. Nearly 2 million kids and 15 million adults thus face a significantly higher risk of contracting measles and of much more severe disease despite vaccination.

Benjamin Mazer avatar
⟳ Bimal Desai retweeted
Benjamin Mazer@BenMazer·Nov 17

In 2021, RFK Jr called it “propaganda” that the measles vaccine was safe and effective, and called the shot “largely unnecessary.”

Post attachment

We will stop measles outbreaks, protect American families, and work to regain U.S. measles elimination status. I continue to recommend MMR vaccination as the most effective way to prevent measles. Worldwide COVID-era disruptions interrupted routine childhood vaccination, leaving gaps in protection here and abroad. The multi-year global outbreak has caused many nations to lose their elimination status including, Armenia, Austria, Azerbaijan, Bolivia, Canada, Mexico, Spain, United Kingdom, and Uzbekistan. Under Dr. Schwartz’s leadership, CDC has provided approximately $100 million in additional funding since August to strengthen prevention and response to measles and other vaccine-preventable diseases. CDC has worked alongside state teams in Texas, South Carolina, Virginia, Kansas, New Mexico, and Wisconsin to help bring their outbreaks rapidly and successfully under control. CDC is also supporting Pennsylvania and New York with epidemiologists and other experts. We are working to close vaccination gaps and rebuild public trust. We will answer families’ questions honestly about vaccine benefits and risks and work with trusted health care providers and community leaders to prevent measles, limit its spread, and support timely treatment. We will support Americans who become ill, regardless of vaccination status, and for the first time equip health care providers with guidance to diagnose and treat measles and its complications.

Melinda B. Chu avatar
⟳ Bimal Desai retweeted
Melinda B. Chu@MelindaBChu1·Nov 17

Q: Why did Anthropic not do the next step, which apparently is $14,000 and only takes 13 days? A: They do not want to be seen as average or mediocre, so they only post vague incomplete things while also aura-farming off of important work by calling things “CRISPR-like” People always say: “well the next step is expensive and takes too long. It’s not Anthropic’s fault they didn’t do it.” They have $100 billion in cash and their report was posted on Sept. 24, almost 2 months ago.

In September, @AnthropicAI announced that its AI agents had found a reverse transcriptase alongside a novel CRISPR-like genetic array in phage DNA. What it actually does, the paper said, would “await experimental characterization.” So we tested it on Ginkgo’s Cloud Lab. Scientists at Ginkgo wrapped Claude Opus 5 in a harness, provided it with the preprint and a catalog of validated workflows in the Ginkgo Cloud Lab, and asked it to generate executable work orders. We ran the first set of these experiments and obtained the first evidence of biochemical activity 13 days after experimental design using about $14,000 of cloud lab services. Read the full write-up: cloud.ginkgo.bio/blog/art-re… You can run your own experiments on our Cloud Lab from anywhere today: cloud.ginkgo.bio

2:59
FBI Dallas avatar
⟳ Bimal Desai retweeted
FBI Dallas@FBIDallas·Nov 17

The #FBI issued a FLASH advisory warning that cybercriminals and state-aligned hackers are exploiting ARTEX, a super intelligence-powered penetration testing framework, to automate attacks against businesses and organizations worldwide. ARTEX can accelerate intrusions from initial targeting to privileged access in under three hours. It was used in the October ConnectWise supply-chain compromise, which exposed Microsoft 365 customer environments and involved attempted authentication against more than 2,250 downstream tenants. The FBI is urging businesses and organizations to strengthen access controls, monitor suspicious automated activity, and report potential compromises to ic3.gov. Read more here: ic3.gov/CSA/2026/261113.pdf

Post attachment
Bimal Desai avatar
Bimal Desai@bimald·Nov 17

Jeez

We break: The highly classified network that the National Security Agency uses for its internal communications is down, according to five people familiar with the matter. The network, called NSA Net, allows employees to communicate classified information internally. At this point there is no evidence of a cyberattack, sources said. As the agency works to understand the scope of the problem, it has enacted staggered arrivals for personnel, the sources said. CNN has asked the National Security Agency for comment. cnn.com/2026/11/17/politics/…

Jordan McGillis avatar
⟳ Bimal Desai retweeted
Jordan McGillis@jordanmcgillis·Nov 17

There's this idea on the right that the entire H-1B program is a scam, that the (predominantly) Indian workers who come to the U.S. on the H-1B aren't actually skilled at all. This is false. H-1B visa holders' marketable skills are demonstrated by their very high earnings.

Post attachment